why choose us

300×250 Ad Slot

Research Article: Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China

Date Published: 2024-05-21

Abstract:
Introduction: The treatment preferences of Chinese physicians who treat nonmetastatic castration-resistant prostate cancer (nmCRPC) and how they weigh the benefits and risks of nmCRPC treatment are still unknown. This study aimed to evaluate Chinese physicians’ benefit–risk treatment preferences for nmCRPC and assist in setting nmCRPC treatment goals.

No summary available.

300×250 Ad Slot